Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. The new formulation is expected to deliver the same efficacy and safety profile of DAYBUE oral solution, while offering children and adults living.

Business Wire • Dec 12, 2025

Why Is Acadia (ACAD) Up 22.6% Since Last Earnings Report?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 5, 2025

Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality

Acadia Pharmaceuticals Inc. is rated Buy for its steady NUPLAZID/DAYBUE franchises and pipeline-driven upside potential. NUPLAZID's patent protection now extends to 2030, supporting >10% Y/Y revenue growth and providing a stable revenue base. DAYBUE missed launch expectations but remains a durable rare-disease asset; ex-U.S. growth is likely to be modest.

Seeking Alpha • Dec 4, 2025

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?

Connecticut-based fund Braidwell bought 2,378,655 shares of Acadia Pharmaceuticals in the third quarter, representing a new position valued at about $50.8 million as of September 30. The transaction represents 2.1% of reportable AUM as of September 30.

The Motley Fool • Dec 4, 2025

ACADIA Pharmaceuticals Inc. (ACAD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

ACADIA Pharmaceuticals Inc. (ACAD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seeking Alpha • Dec 2, 2025

Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Nov 28, 2025

Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Citi's 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 9:45 a.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceutical.

Business Wire • Nov 20, 2025

Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Nov 12, 2025

ACADIA Pharmaceuticals Inc. (ACAD) Presents at UBS Global Healthcare Conference 2025 Transcript

ACADIA Pharmaceuticals Inc. ( ACAD ) UBS Global Healthcare Conference 2025 November 10, 2025 2:00 PM EST Company Participants Mark Schneyer - Executive VP & CFO Ponni Subbiah Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Okay. Good day, everybody.

Seeking Alpha • Nov 10, 2025

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Earnings Call Transcript

ACADIA Pharmaceuticals Inc. ( ACAD ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Albert Kildani Catherine Owen Adams - CEO & Director Thomas Garner - Executive VP & Chief Commercial Officer Elizabeth Thompson - Executive VP and Head of Research & Development Mark Schneyer - Executive VP & CFO Conference Call Participants Ritu Baral - TD Cowen, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Brian Abrahams - RBC Capital Markets, Research Division So Youn Shim - UBS Investment Bank, Research Division Samuel Beck - Deutsche Bank AG, Research Division Malcolm Hoffman - BMO Capital Markets Equity Research Sean Laaman - Morgan Stanley, Research Division Tazeen Ahmad - BofA Securities, Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Julian Hung - Stifel Nicolaus Canada Inc., Research Division Basma Radwan Ibrahim - Leerink Partners LLC, Research Division Poorna Kannan - Needham & Company, LLC, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Sumant Kulkarni - Canaccord Genuity Corp., Research Division Presentation Operator Good day, ladies and gentlemen, and thank you for standing by.

Seeking Alpha • Nov 6, 2025